Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03228914 · ClinicalTrials.gov registry record · Phase 4

Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery

A Phase 4 study of Nasal Polyps and Endoscopic Sinus Surgery, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT03228914 is a Phase 4 study of Nasal Polyps and Endoscopic Sinus Surgery that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 20 participants, below the 100-participant average among 7 other Nasal Polyps trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03228914, a Phase 4 study of Nasal Polyps and Endoscopic Sinus Surgery, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the effects of Oxymetazoline and Epinephrine (which are 2 different nasal decongestants both of which are routinely used before sinus surgery) on blood loss and the surgeon's view of the surgical field during sinus surgery.

Interventions

  • DRUG Epinephrine
  • DRUG Oxymetazoline

Study Locations (1)

Texas

  • The University of Texas Health Science Center at Houston - Houston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2018-06-14
Est. Completion 2018-08-29
Phase Phase 4

What the Registry Record Tells You About NCT03228914

The ClinicalTrials.gov registry entry for NCT03228914 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 7 other Nasal Polyps trials with a reported enrollment target (80% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Nasal Polyps appearing as the primary indexed condition, and to 2 interventions - of which Epinephrine is the first listed.

NCT03228914 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03228914 about?

NCT03228914 is a clinical study titled "Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery". The purpose of this study is to compare the effects of Oxymetazoline and Epinephrine (which are 2 different nasal decongestants both of which are routinely used before sinus surgery) on blood loss and the surgeon's view of the surgical field during sinus surgery.

What is the current status of trial NCT03228914?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2018-06-14. Estimated completion is 2018-08-29.

What conditions does trial NCT03228914 study?

This clinical trial studies the following conditions: Nasal Polyps, Endoscopic Sinus Surgery.

What interventions are being tested in trial NCT03228914?

The interventions under investigation include: Epinephrine (DRUG), Oxymetazoline (DRUG).

Who is sponsoring clinical trial NCT03228914?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03228914 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nasal Polyps

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.